Repositorio Dspace

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial

Mostrar el registro sencillo del ítem

dc.contributor.author Capdevila, Jaume
dc.contributor.author Hernando, Jorge
dc.contributor.author Molina-Cerillo, Javier
dc.contributor.author Plana-Serrahima, María
dc.contributor.author Taberna-Sanz, Miren
dc.contributor.author Castelo, Beatriz
dc.contributor.author Álvarez-Escola, Cristina
dc.contributor.author Carmona-Bayonas, Alberto
dc.contributor.author Ballester-Navarro, Inmaculada
dc.contributor.author Iglesias, Lara
dc.contributor.author Bover, Mateo
dc.contributor.author García-Álvarez, Alejandro
dc.contributor.author Lavernia, Javier
dc.contributor.author Yaya-Tur, Ricardo
dc.contributor.author Ruiz, Sofía
dc.contributor.author Baste, Neus
dc.contributor.author Lorenzo-Lorenzo, Isabel
dc.contributor.author Sánchez-Hernández, Alfredo
dc.contributor.author Sanz-García, Enrique
dc.contributor.author Marquina, Gloria
dc.contributor.author Nuciforo, Paolo
dc.contributor.author Elguero, Belén
dc.contributor.author Grande, Enrique
dc.contributor.author Alonso-Gordoa, Teresa
dc.date.accessioned 2026-08-03T10:27:00Z
dc.date.available 2026-08-03T10:27:00Z
dc.date.issued 2026-04-04
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/27164
dc.description.abstract Single-agent PD-1 blockade demonstrated promising efficacy in advanced thyroid cancer. The phase II, single-arm, multi-cohort GETNE-DUTHY trial (clinicaltrials.gov NCT03753919, EudraCT 2018-001066-42) aimed to determine whether dual anti-PD-L1/CTLA-4 inhibition using durvalumab and tremelimumab can improve the clinical outcomes in advanced thyroid cancer. Three parallel cohorts including patients with differentiated thyroid carcinoma (Cohort 1, n = 37), medullary thyroid carcinoma (Cohort 2, n = 30), and anaplastic thyroid carcinoma (Cohort 3, n = 12) were recruited. Cohort 1 and 2 included patients following progression to previous standard systemic therapy and in Cohort 3 were recruited regardless of previous therapy. The primary endpoint was 6-month progression-free survival rate for Cohort 1 and 2 and 6-month overall survival rate for Cohort 3. Secondary endpoints included objective response rate, progression-free survival, overall survival, and safety. The 6-month progression-free survival rates were 32.4% (95% confidence interval [CI]: 20.4-51.6) (Cohort 1) and 40.8% (95% CI: 26.3-63.6) (Cohort 2); 6-month overall survival rate was 65.6% (95% CI: 43.2-99.8) (Cohort 3). The objective response rates were 8%, 10%, and 33% for Cohort 1, 2, and 3, respectively. No additional safety signals observed. Durvalumab plus tremelimumab treatment in patients with anaplastic thyroid carcinoma met the primary endpoint of this study, showing encouraging survival outcomes.
dc.language.iso eng
dc.publisher SPRINGERNATURE
dc.rights Atribución/Reconocimiento 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.subject.mesh Adult
dc.subject.mesh Aged
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh Male
dc.subject.mesh Middle Aged
dc.subject.mesh Antibodies, Monoclonal/administration & dosage/adverse effects
dc.subject.mesh Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects
dc.subject.mesh Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects
dc.subject.mesh Carcinoma, Neuroendocrine/drug therapy/pathology/mortality
dc.subject.mesh Progression-Free Survival
dc.subject.mesh Thyroid Carcinoma, Anaplastic/drug therapy/pathology/mortality
dc.subject.mesh Thyroid Neoplasms/drug therapy/pathology/mortality
dc.subject.mesh Treatment Outcome
dc.title Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 41935063
dc.relation.publisherversion https://www.nature.com/articles/s41467-026-71155-y
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1038/s41467-026-71155-y
dc.journal.title NATURE COMMUNICATIONS
dc.identifier.essn 2041-1723


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta